LogoPressRelease.jpg
Fluidigm and SIgN Establish the First Center of Excellence in Singapore to Advance Imaging Mass Cytometry
11 mars 2020 08h30 HE | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
LogoPressRelease.jpg
Fluidigm to Participate in Upcoming Investor Conferences
12 févr. 2020 16h05 HE | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
LogoPressRelease.jpg
Fluidigm Announces Fourth Quarter and Full Year 2019 Financial Results
10 févr. 2020 16h05 HE | Fluidigm Corporation
Fourth quarter revenue of $32.4 million Full year 2019 revenue increased 4 percent to $117.2 million; full year mass cytometry revenue increased 23 percent Landmark Nature publication demonstrates...
LogoPressRelease.jpg
Fluidigm Establishes Center of Excellence at NCI-Designated Comprehensive Cancer Center to Advance Imaging Mass Cytometry
10 févr. 2020 16h02 HE | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
LogoPressRelease.jpg
Landmark Nature Publication Demonstrates the Power of the Fluidigm Hyperion Imaging System to Identify Novel Cellular Signatures That Correlate with Distinct Clinical Outcomes
20 janv. 2020 11h32 HE | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), the global leader in high-multiplex single-scan tissue imaging, today announced that a new landmark...
LogoPressRelease.jpg
Fluidigm Provides Preliminary Financial Results for Fourth Quarter and Fiscal Year 2019
14 janv. 2020 08h30 HE | Fluidigm Corporation
Fourth quarter preliminary revenue of $32.0-32.4 million Fiscal year preliminary revenue of $116.7-117.2 million Mass cytometry revenue increased approximately 23 percent for the full fiscal year ...
LogoPressRelease.jpg
Fluidigm Expands Maxpar Antibody Portfolio for High-Multiplex Tissue Imaging
10 déc. 2019 08h30 HE | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), the global leader in high-multiplex single-scan tissue imaging, today announced the availability of...
LogoPressRelease.jpg
Fluidigm to Participate in the 31st Annual Piper Jaffray Healthcare Conference
13 nov. 2019 16h05 HE | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
LogoPressRelease.jpg
Fluidigm Announces Third Quarter 2019 Financial Results
05 nov. 2019 16h05 HE | Fluidigm Corporation
Third quarter revenue decreased 8.5 percent to $26.5 million; year-to-date revenue increased 5 percent to $84.8 million Third quarter consumables revenue increased 11 percent Year-to-date mass...
LogoPressRelease.jpg
Fluidigm Announces Conference Call and Webcast of Third Quarter 2019 Financial Results
10 oct. 2019 16h10 HE | Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...